S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
"Prepare for Five Years of Famine" (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
"Prepare for Five Years of Famine" (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
"Prepare for Five Years of Famine" (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
"Prepare for Five Years of Famine" (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
"Prepare for Five Years of Famine" (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
"Prepare for Five Years of Famine" (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
"Prepare for Five Years of Famine" (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
"Prepare for Five Years of Famine" (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
NASDAQ:MYGN

Myriad Genetics - MYGN Stock Forecast, Price & News

$23.23
+0.70 (+3.11%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$22.82
▼
$23.44
50-Day Range
$18.18
▼
$23.75
52-Week Range
$13.92
▼
$28.18
Volume
582,596 shs
Average Volume
697,924 shs
Market Capitalization
$1.89 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.20

Myriad Genetics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
12.8% Upside
$26.20 Price Target
Short Interest
Bearish
6.39% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.60
Upright™ Environmental Score
News Sentiment
0.32mentions of Myriad Genetics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$351,429 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.71) to ($0.35) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.72 out of 5 stars

Medical Sector

830th out of 1,004 stocks

Diagnostic Substances Industry

10th out of 14 stocks

See Top Rated MarketRank™ Stocks Here

MYGN stock logo

About Myriad Genetics (NASDAQ:MYGN) Stock

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Receive MYGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter.

MYGN Stock News Headlines

March 31, 2023 | americanbankingnews.com
Myriad Genetics, Inc. (NASDAQ:MYGN) COO Nicole Lambert Sells 6,433 Shares
March 16, 2023 | thestreet.com
Will Myriad Genetics (MYGN) Stock React to Price Target Cut at Jefferies?
April 1, 2023 | Weiss Ratings (Ad)
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
March 3, 2023 | finance.yahoo.com
Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2022 Earnings Call Transcript
March 2, 2023 | finanznachrichten.de
Myriad Genetics, Inc.: Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
March 2, 2023 | finance.yahoo.com
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
March 1, 2023 | finance.yahoo.com
Myriad Genetics (MYGN) Q4 Earnings Top, Gross Margin Falls
March 1, 2023 | finance.yahoo.com
Myriad Genetics (MYGN) Reports Q4 Loss, Tops Revenue Estimates
April 1, 2023 | Weiss Ratings (Ad)
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
March 1, 2023 | finance.yahoo.com
Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC
March 1, 2023 | finance.yahoo.com
Q4 2022 Myriad Genetics Inc Earnings Call
February 28, 2023 | markets.businessinsider.com
Myriad Genetics Inc. Q4 Loss Increases, but beats estimates
February 28, 2023 | msn.com
Myriad Genetics Non-GAAP EPS of -$0.12 beats by $0.05, revenue of $177.8M beats by $8.38M
February 28, 2023 | finance.yahoo.com
Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes
February 27, 2023 | msn.com
Earnings Preview For Myriad Genetics
February 23, 2023 | seekingalpha.com
MYGN Myriad Genetics, Inc.
February 22, 2023 | finance.yahoo.com
Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023
February 21, 2023 | uk.finance.yahoo.com
Myriad Genetics, Inc. (MYGN)
February 18, 2023 | marketwatch.com
Ancestry Testing Market by Manufacturers like 23andMe, MyHeritage, LabCorp, Myriad Genetics
February 9, 2023 | finance.yahoo.com
Myriad Genetics to Participate in Upcoming Healthcare Conferences
January 18, 2023 | seekingalpha.com
Natera, Myriad upgraded as Raymond James reviews genetic testing space
January 18, 2023 | finance.yahoo.com
Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock
January 10, 2023 | finance.yahoo.com
Myriad Genetics (MYGN) Ailed by Mounting Costs, FX Headwind
January 5, 2023 | finance.yahoo.com
Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities
January 4, 2023 | finance.yahoo.com
Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference
January 4, 2023 | finance.yahoo.com
Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference
December 25, 2022 | thestreet.com
Myriad Genetics (MYGN) Shows Signs Of Being Water-Logged And Getting Wetter
See More Headlines
Receive MYGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter.

MYGN Company Calendar

Last Earnings
11/02/2021
Today
4/01/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Diagnostic substances
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MYGN
CUSIP
62855J10
CIK
899923
Web
www.myriad.com
Phone
(801) 584-3600
Fax
801-584-3640
Employees
2,600
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$26.20
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$23.00
Forecasted Upside/Downside
+12.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.39)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-112,000,000.00
Net Margins
-16.51%
Pretax Margin
-20.73%
Return on Equity
-5.83%
Return on Assets
-4.42%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.00
Quick Ratio
1.85

Sales & Book Value

Annual Sales
$678.40 million
Price / Sales
2.78
Cash Flow
$0.19 per share
Price / Cash Flow
121.67
Book Value
$10.93 per share
Price / Book
2.13

Miscellaneous

Outstanding Shares
81,220,000
Free Float
79,762,000
Market Cap
$1.89 billion
Optionable
Optionable
Beta
1.82

Social Links


Key Executives

  • Paul J. Diaz
    President, Chief Executive Officer & Director
  • Nicole LambertNicole Lambert
    Chief Operating Officer
  • R. Bryan Riggsbee
    Chief Financial Officer, Treasurer & Executive VP
  • Dale Muzzey
    Chief Scientific Officer
  • Kevin R. Haas
    Chief Technology Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













MYGN Stock - Frequently Asked Questions

Should I buy or sell Myriad Genetics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MYGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares.
View MYGN analyst ratings or view top-rated stocks.

What is Myriad Genetics' stock price forecast for 2023?

4 analysts have issued 1-year price objectives for Myriad Genetics' stock. Their MYGN share price forecasts range from $23.00 to $32.00. On average, they predict the company's stock price to reach $26.20 in the next year. This suggests a possible upside of 12.8% from the stock's current price.
View analysts price targets for MYGN or view top-rated stocks among Wall Street analysts.

How have MYGN shares performed in 2023?

Myriad Genetics' stock was trading at $14.51 at the start of the year. Since then, MYGN shares have increased by 60.1% and is now trading at $23.23.
View the best growth stocks for 2023 here.

When is Myriad Genetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our MYGN earnings forecast.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) released its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.02). The company earned $167.30 million during the quarter, compared to analyst estimates of $164.35 million. Myriad Genetics had a negative net margin of 16.51% and a negative trailing twelve-month return on equity of 5.83%. During the same period in the prior year, the business earned ($0.19) earnings per share.

What ETFs hold Myriad Genetics' stock?

ETFs with the largest weight of Myriad Genetics (NASDAQ:MYGN) stock in their portfolio include Psyk Etf (PSYK), Global X Genomics & Biotechnology ETF (GNOM), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).

What guidance has Myriad Genetics issued on next quarter's earnings?

Myriad Genetics issued an update on its first quarter 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share (EPS) guidance of -$0.20--$0.18 for the period, compared to the consensus EPS estimate of -$0.10. The company issued revenue guidance of $170.00 million-$172.00 million, compared to the consensus revenue estimate of $174.88 million.

What is Paul Diaz's approval rating as Myriad Genetics' CEO?

12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Myriad Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS).

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

How do I buy shares of Myriad Genetics?

Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Myriad Genetics' stock price today?

One share of MYGN stock can currently be purchased for approximately $23.23.

How much money does Myriad Genetics make?

Myriad Genetics (NASDAQ:MYGN) has a market capitalization of $1.89 billion and generates $678.40 million in revenue each year. The company earns $-112,000,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis.

How many employees does Myriad Genetics have?

The company employs 2,600 workers across the globe.

Does Myriad Genetics have any subsidiaries?
The following companies are subsidiares of Myriad Genetics: Assurex Health Inc., Assurex Health Ltd, Counsyl, Crescendo Bioscience, Crescendo Bioscience LLC, Javelin Pharmaceuticals, Myriad Autoimmune, Myriad Genetic Laboratories Inc., Myriad Genetics Australia PTY LTD, Myriad Genetics B.V., Myriad Genetics Canada Corp, Myriad Genetics Espana SL, Myriad Genetics GK, Myriad Genetics GmbH, Myriad Genetics LTD, Myriad Genetics S.r.l., Myriad Genetics SAS, Myriad GmbH, Myriad International GmbH, Myriad Neuroscience, Myriad Services GmbH, Myriad Women’s Health, Myriad Women’s Health Inc, NaturNorth Technologies, Privatklinik Dr. Robert Schindlbeck, Rules-Based Medicine, and Sividon Diagnostics.
Read More
How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The official website for the company is www.myriad.com. The company can be reached via phone at (801) 584-3600, via email at sgleason@myriad.com, or via fax at 801-584-3640.

This page (NASDAQ:MYGN) was last updated on 4/1/2023 by MarketBeat.com Staff